Oncotarget

Research Papers:

Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers

William M. Strauss _, Chris Carter, Jill Simmons, Erich Klem, Nathan Goodman, Behrad Vahidi, Juan Romero, Michael Masterman-Smith, Ruth O'Regan, Keerthi Gogineni, Lee Schwartzberg, Laura K. Austin, Paul W. Dempsey, Massimo Cristofanilli

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2016; 7:26724-26738. https://doi.org/10.18632/oncotarget.8494

Metrics: HTML 1502 views  |   ?  


Abstract

William M. Strauss1, Chris Carter1, Jill Simmons1, Erich Klem1, Nathan Goodman2, Behrad Vahidi1, Juan Romero1,8, Michael Masterman-Smith1, Ruth O’Regan3, Keerthi Gogineni4, Lee Schwartzberg5, Laura K. Austin6, Paul W. Dempsey1, Massimo Cristofanilli7

1Cynvenio Biosystems, Westlake Village, CA, 91361, USA

2Independent, Seattle, WA, 98109, USA

3Department of Hematology and Medical Oncology, Winship Cancer Center, Emory University, Atlanta, GA, 30322, USA

4Division of Hematology/Oncology, University of Wisconsin, Madison, WI, 53792, USA

5The West Clinic, Germantown, TN, 38138, USA

6Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA,19107, USA

7Lurie Cancer Center, Northwestern University, Chicago, IL, 60611, USA

8Current Address: Xencor, Inc, Monrovia, CA 91016, USA

Correspondence to:

Paul W. Dempsey, e-mail: pdempsey@cynvenio.com

Keywords: liquid biopsy, CTC, cfDNA, metastatic breast cancer, next generation sequence

Received: December 23, 2015    Accepted: March 14, 2016    Published: March 30, 2016

ABSTRACT

Targeted cancer therapeutics are promised to have a major impact on cancer treatment and survival. Successful application of these novel treatments requires a molecular definition of a patient’s disease typically achieved through the use of tissue biopsies. Alternatively, allowing longitudinal monitoring, biomarkers derived from blood, isolated either from circulating tumor cell derived DNA (ctcDNA) or circulating cell-free tumor DNA (ccfDNA) may be evaluated. In order to use blood derived templates for mutational profiling in clinical decisions, it is essential to understand the different template qualities and how they compare to biopsy derived template DNA as both blood-based templates are rare and distinct from the gold-standard. Using a next generation re-sequencing strategy, concordance of the mutational spectrum was evaluated in 32 patient-matched ctcDNA and ccfDNA templates with comparison to tissue biopsy derived DNA template. Different CTC antibody capture systems for DNA isolation from patient blood samples were also compared. Significant overlap was observed between ctcDNA, ccfDNA and tissue derived templates. Interestingly, if the results of ctcDNA and ccfDNA template sequencing were combined, productive samples showed similar detection frequency (56% vs 58%), were temporally flexible, and were complementary both to each other and the gold standard. These observations justify the use of a multiple template approach to the liquid biopsy, where germline, ctcDNA, and ccfDNA templates are employed for clinical diagnostic purposes and open a path to comprehensive blood derived biomarker access.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8494